Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Procedure of the Annual General Meeting

CHEMMRegulatory press release08.10.2026 klo 20.57

ANNOUNCEMENT NO. 319

8 October 2026


The Annual General Meeting of ChemoMetec A/S was held on 8 October 2026 at 17:30 at Nordsjællands KonferenceCenter.

At the Annual General Meeting, the Board of Directors' report on the company's activities during the past year was presented, the annual report for 2025/26 was approved, and the Board of Directors and the Executive Board were granted discharge.

The General Meeting approved the Board of Directors’ proposal for the appropriation of profit in accordance with the annual report, including that no dividend be paid for the financial year 2025/26.

The proposal presented by the Board of Directors that the Board of Directors continues to consist of 5 members was approved. Niels Thestrup, Martin Glensbjerg, Kristine Færch, Betina Hagerup and Peter Reich were re-elected to the Board of Directors.

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was elected as the company’s auditor.

The Annual General Meeting approved the remuneration report, presented by the Board of Directors.

The proposal presented by the Board of Directors to authorise the Board of Directors to acquire the company’s own shares on behalf of the company was approved.

There were no other items for consideration, after which the general meeting was adjourned.

After the general meeting, a statutory board meeting was held, where Niels Thestrup was re-elected as chairman and Martin Glensbjerg as deputy chairman.


Additional Information

Martin Helbo Behrens, CEO
Tel.: (+45) 81 10 06 80 

Phillip Massie Price, CFO
Tel.: (+45) 81 10 06 80 


About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

Attachment

  • Procedure of the Annual General Meeting